NGS

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays

Retrieved on: 
Thursday, April 4, 2024
PCR, QC, Gene, Data analysis, RT, Bias, BCR, Calibration, NGS, Biomarker, Research, RNA, Messenger, Workflow, Immunity, TCR, Collection, AIR, Vaccine

MOUNTAIN VIEW, Calif., April 4, 2024 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.

Key Points: 
  • The first-to-market DriverMap™ AIR RNA TCR/BCR spike-in calibration controls measure the accuracy, sensitivity, and linear range of sequencing-based immune repertoire profiling assays.
  • The DriverMap™ AIR RNA Spike-In Controls' key characteristics include:
    These controls consist of 48 B-Cell Receptor (BCR) and 39 T-Cell Receptor (TCR) synthetic mRNA constructs designed to mimic all the different and most abundant TCR and BCR genes.
  • These standards and controls will help attain the goal of more reliable and reproducible AIR sequencing (AIR-Seq) data harmonization, interpretation, and sharing.
  • For more information on the DriveMap AIR RNA Spike-In Controls, including introductory pricing, visit www.cellecta.com/DriverMapAIR or email [email protected] .

SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024

Retrieved on: 
Wednesday, April 3, 2024
Health, Growth, Capsule, Probiotic, NGS, Research, Lactic acid, Interview, Kansas City Convention Center, DNA sequencing, Immunity, Facial muscles, Fermentation, Pet, Aggression

TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.

Key Points: 
  • TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based in Taiwan, is proud to announce its participation at the upcoming Petfood Forum 2024.
  • At Petfood Forum 2024, SYNPET will showcase its headlining product:
    GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior.
  • "We are thrilled to participate in Petfood Forum 2024 and introduce our innovative probiotic solutions to the pet food industry," said Tammy Chang, Vice President of SYNBIO TECH.
  • For media inquiries or to schedule an interview with SYNPET representatives at Petfood Forum 2024, please contact:

Biofidelity raises $24 million in new financing to accelerate commercialization and expand product pipeline

Retrieved on: 
Wednesday, April 3, 2024
Lung cancer, LBA, Conference, Growth, NSCLC, Partnership, Patient, NGS, Biomarker, Research, Octopus Group, Laboratory, Medicine, AACR, Agilent Technologies, Pharmaceutical industry

Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.

Key Points: 
  • Additionally, the new investment will enable the establishment of a dedicated manufacturing facility in the United Kingdom and drive pipeline expansion efforts across the Company's innovative technology platforms.
  • "This significant investment underlines the confidence of our investors in Biofidelity's unique technologies and our mission to bring the benefits of precision medicine to all patients," said Biofidelity Co-Founder and CEO Dr. Barnaby Balmforth.
  • The new funding round includes fresh commitments from current investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
  • "We are thrilled to continue our partnership with Biofidelity as the team embarks on the next phase of their growth and commercial expansion."

Laboratorio Barnafi-Krause is Live on SOPHiA DDM™

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, CLL, Leukemia, Incidence, Technical, Patient, NGS, Research, Death, GENETICS, Sophia Genetics, Unit production manager, Chronic lymphocytic leukemia, Bone marrow, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.

Key Points: 
  • BOSTON and ROLLE, Switzerland, April 2, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform.
  • Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.
  • With the SOPHiA DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored NGS-based workflows that enable accurate and sensitive characterization of the complex mutational landscape associated with blood disorders.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Thursday, March 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

DNA Nanotechnology Market worth $24.3 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Thursday, March 21, 2024
Growth, Biotechnology, Danaher Corporation, NGS, Electronics, DNA, Research, Nanotechnology, Acquisition, Cancer, Messenger, Protein, Report, Medicine

The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.

Key Points: 
  • The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.
  • Significant factors fueling the market's growth include innovation, as mentioned earlier, potential, and the rising investment in nanotechnology research driven by the growth of DNA nanotechnology.
  • The North American DNA nanotechnology market is anticipated to record a maximum market share in terms of revenue.
  • Besides, Asia Pacific had a considerable market share in the market due to generating DNA nanotechnology solutions, which is encouraged by the expansion of nanotechnology, which stimulates collaboration between varied research groups and industries in this region.

DNA Nanotechnology Market worth $24.3 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Thursday, March 21, 2024
Growth, Biotechnology, Danaher Corporation, NGS, Electronics, DNA, Research, Nanotechnology, Acquisition, Cancer, Messenger, Protein, Agilent Technologies, Report, Medicine

The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.

Key Points: 
  • The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.
  • Significant factors fueling the market's growth include innovation, as mentioned earlier, potential, and the rising investment in nanotechnology research driven by the growth of DNA nanotechnology.
  • The North American DNA nanotechnology market is anticipated to record a maximum market share in terms of revenue.
  • Besides, Asia Pacific had a considerable market share in the market due to generating DNA nanotechnology solutions, which is encouraged by the expansion of nanotechnology, which stimulates collaboration between varied research groups and industries in this region.